化学
氧化呋咱环
一氧化氮
体内
赫拉
铅化合物
药理学
生物活性
IC50型
毒性
体外
立体化学
组合化学
生物化学
有机化学
医学
生物技术
生物
作者
Yingda Zang,Lei Huang,Xinyi Chen,Chuang‐Jun Li,Jie Ma,Xiaoguang Chen,Dongming Zhang,Fangfang Lai
标识
DOI:10.1016/j.ejmech.2022.114832
摘要
In this study, a series of novel furoxan-based nitric oxide (NO) releasing derivatives of pyranocarbazole alkaloids were designed, synthesized, and biologically evaluated against human cancer cell lines. The derivatives showed considerable antiproliferative activities (IC50 = 0.05–7.55 μM) and most compounds showed higher activity in MDA-MB-231 than H460 and HeLa. Especially, the most active derivative 7a (IC50 = 0.05 μM) against MDA-MB-231 was about 60 times stronger than lead compound, as well as equivalent to positive control taxol, and produced high levels of NO in MDA-MB-231. Furthermore, 7a could significantly inhibit the growth of MDA-MB-231 tumors in vivo with low toxicity and the PI3K/Akt signaling pathway. These results indicated that compound 7a could be a promising lead for further studies.
科研通智能强力驱动
Strongly Powered by AbleSci AI